COMP <GO>
GENI vs BRSL // EV/EBITDA & P/E VALUATION
Genius Sports Limited (NYSE) VS. Brightstar Lottery PLC Trading under the Legal Name to begin at the market open on July 21 2025. (NYSE) • 15-METRIC TALLY: GENI 4
— BRSL 3
■ METRIC PARITY
LAST: $6.46 (+1.73%) • MKT CAP: $1.73B
valuation
—
BRSL — Brightstar Lottery PLC Trading under the Legal Name to begin at the market open on July 21 2025.
ROARABLE D • RQD 49/100
LAST: $9.60 (+3.34%) • MKT CAP: $1.77B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GENI VS. BRSL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GENI | BRSL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 23.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -26.90% | 16.80% | -43.70 | BRSL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.73% | -5.59% | +9.32 | GENI | /fcf-yield <GO> |
| Operating Margin | -22.60% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -16.70% | 5.90% | -22.60 | BRSL | /net-margins <GO> |
| Revenue Growth (YoY) | 31.00% | 0.00% | +31.00 | GENI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.43 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 1/9 | +4.00 | GENI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.2 | 46.4 | +1.73 | GENI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 11.2x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.73B | $1.77B | -$42.3M | BRSL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GENI REV | BRSL REV | GENI GROSS % | BRSL GROSS % | GENI FCF | BRSL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $669.5M | $2.51B | 23.0% | — | $64.5M | -$99.0M |
| FY 2024 | $510.9M | $2.51B | 25.2% | — | $69.6M | $1.05B |
| FY 2023 | $413.0M | $2.53B | — | — | $14.9M | $1.01B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GENI // BETA —
BRSL // BETA —